- Home
- UAA vs CLDX Comparison
UAA vs CLDX Comparison
Compare UAA & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UAA | CLDX |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | 14100 | N/A |
| Industry | Apparel | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | UAA | CLDX |
|---|---|---|
| Price | $7.04 | $35.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 10 |
| Target Price | $6.48 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 7.5M | 1.2M |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,743,000.00 |
| Revenue This Year | N/A | $111.39 |
| Revenue Next Year | $1.57 | $235.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 87.78 |
| 52 Week Low | $4.13 | $19.72 |
| 52 Week High | $8.15 | $40.30 |
Technical Indicators
Market Signals| Indicator | UAA | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 56.23 | 47.26 |
| Support Level | $6.01 | $28.51 |
| Resistance Level | $7.50 | $35.10 |
| Average True Range (ATR) | 0.34 | 1.67 |
| MACD | -0.01 | -0.59 |
| Stochastic Oscillator | 54.66 | 24.46 |
Price Performance
Historical ComparisonAbout UAA Under Armour Inc.
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 440 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.